Immunotherapy Is Entering the Stage 3 Lung Cancer Landscape – Curetoday.com
OncLive |
Immunotherapy Is Entering the Stage 3 Lung Cancer Landscape
Curetoday.com Imfinzi (durvalumab), a PD-L1 inhibitor, is being reviewed for a supplemental biologics license application (sBLA) by the Food and Drug Administration (FDA) for the treatment of patients with stage 3, unresectable non-small cell lung cancer (NSCLC … Immunotherapy/RT Combos Could Be Next Wave of Novel Treatment in Lung Cancers |
